Sector News

AstraZeneca seals Aspen Global anesthetics deal

June 9, 2016
Life sciences

Pharmaceutical giant AstraZeneca PLC said Thursday it has reached an agreement with Aspen Pharmacare Holdings Ltd. giving the Johannesburg-listed company rights to its anesthetics portfolio outside the U.S.

Under the deal, Aspen Global Incorporated, a unit of Aspen Pharmacare, will buy commercialization rights outside the U.S. to the portfolio for an upfront payment of $520 million.

Aspen will also pay AstraZeneca up to $250 million in a product sales-related payment, as well as double-digit percentage trademark royalties on product sales.

AstraZeneca said it will manufacture and supply the products on a cost plus basis to Aspen for an initial period of 10 years. Upon completion, Aspen will assume responsibility for all activities relating to the sale of the portfolio in all relevant markets, AstraZeneca added.

The deal isn’t expected to impact AstraZeneca’s financial guidance this year, the company said.

By Ian Walker

Source: MarketWatch

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach